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Background: BRAF inhibitors (BRAFi) improve survival in metastatic melanoma patients (MMP) but the duration of clinic-
al beneﬁt is limited by development of drug resistance. Here, we investigated whether the expression of programmed
death-ligand 1 (PD-L1) and the density of tumor-inﬁltrating mononuclear cells (TIMC) predict the occurrence of resistance,
hence affecting the clinical outcome in BRAFi-treated MMP.
Methods: PD-L1 expression (cutoff 5%) was analyzed by immunohistochemistry with two different antibodies in
BRAFV600-mutated formalin-ﬁxed and parafﬁn-embedded samples from 80 consecutive MMP treated with BRAFi at a
single institution. TIMC were evaluated by conventional hematoxylin and eosin staining.
Results: Forty-six and 34 patients received vemurafenib and dabrafenib, respectively. Membranous expression of PD-
L1 was detected in 28/80 (35%) of patients. At multivariate analysis, absence of tumoral PD-L1 staining [odd ratio (OR)
10.8, 95% conﬁdence interval (CI) 2.7–43.3, P < 0.001] and the presence of TIMC (OR 6.5, 95% CI 1.7–24.3, P < 0.005)
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were associated with a better response to treatment. Median progression-free survival (PFS) and overall survival were 10
and 15 months, respectively. By multivariate assessment, PD-L1 expression [hazard ratio (HR) 4.3, 95% CI 2.1–8.7,
P < 0.0001] and absence of TIMC (HR 2.5, 95% CI 1.4–4.7, P < 0.002) correlated with shorter PFS. PD-L1 overexpres-
sion (HR 6.2, 95% CI 2.8–14.2, P < 0.0001) and absence of TIMC (HR 3.1, 95% CI 1.5–6.5, P < 0.002) were independent
prognostic factors for melanoma-speciﬁc survival.
Conclusion: Our results provide the ﬁrst proof-of-principle evidence for the predictive and prognostic relevance of PD-L1
immunohistochemical expression and density of immune cell inﬁltration in BRAFV600-mutated MMP treated with BRAFi.
Key words:melanoma, PD-L1, immune cell inﬁltration, BRAF inhibitors, resistance, prognosis
introduction
At the disseminated stage, melanoma is an incurable disease.
For several years, according to the results of nonrandomized
clinical trials and meta-analyses, the standard of care of metastatic
melanoma patients (MMP) was limited to the administration of a
single cytotoxic agent, such as dacarbazine, temozolomide or
fotemustine [1].
The understanding of the genetic heterogeneity underlying
melanoma has revolutionized treatment options for MMP. The
discovery that ∼40%–50% MMP harbor BRAF-activating muta-
tions, predominantly at codon 600, has led to the unprecedented
identiﬁcation of a truly actionable molecular target, which even-
tually resulted in the development of BRAF inhibitors (BRAFi).
Seminal clinical trials have shown that treatment of MMP with
two different BRAFi (vemurafenib, dabrafenib) is associated with
improved response rate (RR), progression-free survival (PFS) and
overall survival (OS) compared with conventional chemotherapy
[2, 3]. However, while clinical responses to BRAFi may be dramatic,
with some patients maintaining remission for several months
or years, the median duration of response is between 6 and
7 months [2–4].
In addition to their established molecular mechanism of action,
growing evidence suggests that the therapeutic efﬁcacy of BRAFi
relies on additional factors that affect the tumor–host interactions,
including the enhancement of melanoma antigen expression
and the increase in immune response against tumor cells [5].
Consistently, preclinical data show that oncogenic BRAF contri-
butes to immune evasion, and that targeting this mutation may
increase the melanoma immunogenicity [6]. Within the ﬁrst
2 weeks of therapy, the expression of immunomodulatory mole-
cules on the tumor cell surface, such as programmed death-
ligand 1 (PD-L1 or B7-H1) and programmed death-1 (PD-1) in
T lymphocytes, are increased [5]. Data in vitro or from animal
models propose PD-L1 as a potential mechanism that favors
BRAFi resistance through the modulation of host immune
responses [7]. However, demonstration of this hypothesis in the
clinical setting is lacking.
Recently, we showed that PD-L1 expression is increased in
metastatic melanomas when compared with primary lesions
and that PD-L1 expression behaves as a negative prognostic
factor in MMP [8]. However, our retrospective study had two
potential limitations: (i) the patient cohort, being treated over a
wide time span (20 years), was heterogeneous in terms of treat-
ment and (ii) PD-L1 immunohistochemical (IHC) evaluation
was carried out in both primary and metastatic tissue samples.
With regards to the PD-L1 expression in the context of mel-
anoma, four distinct groups of tumors were identiﬁed and
described as having the presence of both PD-L1 and tumor-
inﬁltrating immune cells (TIMC), presence of TIMC without
PD-L1, PD-L1 expression without TIMC or absence of both
TIMC and PD-L1 expression [9]. These ﬁndings raise important
questions regarding the function and speciﬁcity of TIMC in
PD-L1− tumors and the biological basis for tumors lacking
TIMC. In the latter group, it is not clear whether the lack of
T-cell inﬁltration reﬂects the absence of tumor antigen-speciﬁc
responses or an as-yet unidentiﬁed process that excludes TIMC
from the microenvironment.
In the present study, we have evaluated, in a homogeneous
series of MMP treated with BRAFi, the association of tumoral
PD-L1 IHC expression and the density of TIMC with RR, PFS
and OS. Results provide the ﬁrst proof-of-principle clinical evi-
dence of the predictive and prognostic relevance of PD-L1 IHC
expression and density of immune cell inﬁltration in BRAFV600-
mutated MMP receiving BRAFi.
materials and methods
patients
Cohort characteristics are reported in Supplementary Materials and
Methods (SMM).
tissue samples
Detailed protocols are reported in SMM.
DNA extraction from FFPE tissues and BRAF
mutation detection
Detailed protocols are reported in SMM.
immunohistochemistry
Immunohistochemistry was carried out on 4-µm-thick sections with two
antibodies: the murine anti-human B7-H1 mAb (clone 5H1) with a concen-
tration of 2 µg/ml according to a previously described protocol [10, 11], with
slight modiﬁcation [8], and the rabbit mAb clone E1L3N (dilution 1:50).
Further detailed protocols are reported in SMM.
case evaluation
Detailed protocols are reported in SMM.
statistical analysis
All melanoma patients satisfying eligibility criteria and treated with BRAFi
were considered for analysis. RR was deﬁned as the proportion of patients
with complete response or partial response. PFS was deﬁned as the time
from the beginning of BRAFi to ﬁrst appearance of progressive disease or
death for any cause; patients known to be alive and without progressive
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disease at the time of analysis were censored at their last available follow-up
assessment. PFS and ORR were based on RECIST, v1.1 [12]. OS was deﬁned
as the time from the beginning of BRAFi to the date of death from any cause
or the date of the last follow-up.
Additional statistical methods are delineated in SSM.
results
patients and treatments
Demographic and clinical characteristics of the cohort are sum-
marized in supplementary Table S1, available at Annals of
Oncology online. Just over half (53%) were males and the median
age was 56 years, ranging from 21 to 86 years. All patients had
metastatic disease, over half with M1C disease [56% (44/80)]
according to AJCC VII edition. Forty-six patients (58%) received
vemurafenib, and the remaining cases received dabrafenib. Three
patients received ipilimumab before treatment with BRAFi [two
patients PD-L1+ (7%) and one PD-L1− (2%), respectively]. After
the discontinuation of BRAFi, subsequent anticancer therapy was
administered to 18 patients (22%). Ipilimumab was administered
to ﬁve patients PD-L1+ and four patients PD-L1−; the remaining
cases received dacarbazine or fotemustine.
PD-L1 expression and tumor-inﬁltrating immune
cells in metastatic melanoma samples
PD-L1 IHC and the tumor-inﬁltrating mononuclear immune cells
expression were evaluated in all consecutive, metastatic melanoma
cases. PD-L1 expression on the tumor cell membrane was negative
in 51 patients (64%) and positive in 28 patients (35%). For one
patient, PD-L1 staining was not feasible due to diffuse melanin
pigmentation. Twenty (71%) and 5 (18%) of the PD-L1+ cases
were identiﬁed in patients with stage M1C and M1a, respectively.
PD-L1 expression was evaluated in the last available metastat-
ic sample before starting BRAFi therapy in 63 patients. In the
remaining cases, PD-L1 was evaluated in the primary melanoma
sample due to unavailability of metastatic tissue. The median
time that the biopsies were taken before starting BRAFi treat-
ment of metastatic disease was 2 months (range 1–6 months).
PD-L1 staining patterns in melanoma tissues were similar
with both antibodies; both provided a cell membranous signal,
with variable cytoplasmic reactivity (supplementary Figure S1,
available at Annals of Oncology online). There was a complete
concordance for positivity (cutoff 5%) as well as intensity in the
50/80 (63%) cases that were evaluated with both reagents.
Consistent with previous observations, PD-L1 expression in the
tumor microenvironment was recognized in separated foci
mostly at the borders of melanoma cell aggregates in association
with an intratumoral immune cell inﬁltration (interface or per-
ipheral pattern). However, in some cases, melanoma cells were
diffusely and strongly positive for PD-L1 in the absence of any
inﬂammatory cell component (diffuse pattern) (Figure 1).
Among 80 MMP, 45 showed absent/focal TIMC, while 34 were
associated with at least moderate TIMC among tumor cells. One
case was not evaluable due to diffuse melanin pigmentation.
association of PD-L1 expression and TIMC
To explore a potential association between PD-L1 expression
and the presence of TIMC, we compared the degree of PD-L1
expression to the intensity of associated immune inﬁltrates. We
found that 35% (28/80) of melanoma samples expressed PD-L1
(mean expression in positive samples, 40%; range, 6%–80%).
Interestingly, 30% of the PD-L1+ cases were associated with
TIMC positivity compared with 40% of PD-L1− cases.
correlation between PD-L1 expression and/or
tumor-inﬁltrating mononuclear immune cell
density and RR, DFS and OS
Response to treatment at 2 months, available for all included
patients, was as follows: 8 (10%) complete response; 40 (50%)
partial response; 16 (20%) stable disease and 16 (20%) pro-
gressive disease. Results of multivariate logistic model assessing
the prognostic effect of the presence of PD-L1 expression are
reported in Table 1. At multivariate analysis, PD-L1− [odd ratio
(OR) 10.8, 95% conﬁdence interval (CI) 2.7–43.3, P < 0.001]
and the presence of TIMC (OR 6.5, 95% CI 1.7–24.3, P < 0.005)
were signiﬁcantly associated with a higher probability of respond-
ing to treatment (supplementary Table S2, available at Annals of
Oncology online). At a median follow-up of 9 months, 51 (64%)
patients had progressed and 42 (52.5%) had died. Overall, 55
(69%) patients progressed or died. In the whole group, the median
PFS and OS were 10 and 15 months, respectively. Figure 2 shows
the Kaplan–Meier curves for PFS and OS according to the PD-L1
expression and the presence of TIMC.
At multivariate assessment, PD-L1 expression [hazard ratio
(HR) 4.3, 95% CI 2.1–8.7, P < 0.0001], as well as the absence of
TIMC (HR 2.5, 95% CI 1.4–4.7, P < 0.002), were associated with
a statistically signiﬁcant shorter PFS (Table 1).
In the multivariate model, PD-L1 overexpression (HR 6.2,
95% CI 2.8–14.2, P < 0.0001), as well as the absence of TIMC
(HR 3.1, 95% CI 1.5–6.5, P < 0.002), were independent prognos-
tic factors for melanoma-speciﬁc survival (Table 1).
Finally, PFS and OS were statistically signiﬁcant longer in
PD-L1− and TIMC+ patients than in all other combinations
[(PD-L1+/TIMC−, as well as those PD-L1−/TIMC− or PD-L1+/
TIMC+ (Figure 3)].
discussion
One of the major issues in exploiting BRAFi for MMP lies in
the interpatient degree and duration of response: some patients
derive no beneﬁt, others have a dramatic, complete disappear-
ance of all disease, and the remainder is somewhere in between
[13]. Hence, there is a clinical need to identify biomarkers
that can allow accurate establishment of the best treatment
approach in the individual patient with BRAF-mutated
melanoma.
The most striking ﬁnding of this study is that IHC PD-L1 over-
expression, together with the lack of TIMC in metastatic melan-
oma samples, are associated with resistance and poor prognosis in
MMP receiving BRAFi. This conclusion was reached upon testing
PD-L1 expression in a cohort of 80 consecutive MMP treated at a
single institution, using two validated monoclonal antibodies spe-
ciﬁc for PD-L1.
The same multidisciplinary team evaluated all enrolled
patients. In our center, melanoma patients who do not enter
clinical trials are assessed according to standard internal
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guidelines at baseline and upon treatment. Speciﬁcally, before
starting treatment, all patients underwent total body computed
tomographic (CT), ECG and blood laboratory analysis. Physical
examination, including dermatological evaluation, was carried
out every 4 weeks. The ﬁrst disease assessment was planned
after 8 weeks and thereafter every 12 weeks. The CT scan was
anticipated if there was a suspicion of disease progression and/
or in the presence of worsening symptoms. Overall, the time
schedule for disease assessment was similar for all patients.
There are several biological explanations that support our
clinical data. Suminoto et al. found that oncogenic BRAFV600
can lead to immune escape in melanoma [6], and that blocking
its activity via MAPK pathway inhibition leads to increased
expression of melanocyte differentiation antigens as well as re-
duction of the secretion of immunosuppressive chemokines
such as IL-6/10 [6]. Furthermore, in vivo studies showed that
after 2 weeks from starting BRAFi treatment, there is an increase
in PD-1 expression, coupled with a signiﬁcant increase in the
expression of its ligand PD-L1 within the tumor stroma [5].
Interestingly, in vitro studies showed high PD-L1 expression in
melanoma cell lines resistant to BRAF inhibition [7]. Overall,
the above data support the engagement of a host immune re-
sponse in regressing melanoma during treatment with BRAFi
[5, 14, 15]. This is indirectly conﬁrmed by emerging data strong-
ly suggesting that an increase in the density of tumor-inﬁltrating
lymphocytes within and around metastases in biopsies taken
early after commencement of treatment (within 2 weeks) corre-
lates with response to BRAFi [5].
Our clinical results extend these data and support the hypoth-
esis that a more hostile tumor microenvironment, as well as the
A B
C D
E F
Figure 1. Tumoral PD-L1 expression and immune inﬁltrates in the tumor microenvironment (mouse anti-human B7-H1 mAb, clone 5H1). (A) PD-L1-negative
melanoma metastasis, there are no immune cells in intratumoral location; (B) lack of PD-L1 staining in melanoma cells in association with marked tumor-inﬁltrating
mononuclear cells (TIMC); (C) Mostly membranous PD-L1 staining in melanoma cells in absence of TIMC; (D) PD-L1 expression is recognized mostly at the
borders of melanoma cell aggregates in association with an intratumoral immune cell inﬁltration (interface or peripheral pattern); (E) strong membranous and cyto-
plasmic staining in aggregates of melanoma cells (diffuse pattern) in absence of TIMC; (F) melanoma cells show diffuse PD-L1 positivity in presence of moderate
TIMC inﬁltration (original magniﬁcation ×40, scale bar 50 µm). Asterisks indicate tumor-inﬁltrating mononuclear cells (TIMC).
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Table 1. Multivariate analysis: prognostic factors for PFS and OS
PFS OS
HR (95% CI) P HR (95% CI) P
Sex
Male 1.00 (Ref.) 1.00 (Ref.)
Female 1.24 (0.71–2.17) 0.447 1.84 (0.95–3.57) 0.071
Age (as continuous) 1.03 (1.00–1.05) 0.021 1.03 (1.01–1.06) 0.012
Stage of disease
M1a or M1b 1.00 (Ref.) 1.00 (Ref.)
M1c 2.13 (1.13–0.20) 0.02 2.34 (1.11–4.94) 0.026
PD-L1
Negative 1.00 (Ref.) 1.00 (Ref.)
Positive 4.28 (2.10–8.72) <0.001 6.27 (2.77–14.22) <0.001
TIMC
Present 1.00 (Ref.) 1.00 (Ref.)
Absent 2.59 (1.42–4.73) 0.002 3.11 (1.50–6.48) 0.002
1.00
A B
C D
X2(log-rank) = 18.00, P < 0.001
X2(log-rank) = 18.02, P < 0.001
X2(log-rank) = 11.61, P < 0.001
X2(log-rank) = 11.08, P < 0.001
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Figure 2. Kaplan–Meier curves showing DFS and OS of metastatic melanoma patients (MMP) according to PD-L1 expression (membrane) and density of
tumor-inﬁltrating mononuclear immune cells (TIMC) in melanoma tissue samples. (A) PFS according to membrane PD-L1 immunohistochemical expression
in melanoma tissues (cutoff 5%). (B) PFS according to TIMC density in melanoma tissues. (C) OS according to membrane PD-L1 immunohistochemical ex-
pression in melanoma tissues (cutoff 5%). (D) OS according to TIMC density in melanoma tissues (cutoff 5%).
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overexpression of tumor PD-L1, are associated with a worse RR
and outcome in BRAFV600-mutated MMP receiving BRAFi.
In agreement with previous reports [10, 11], we found that
the expression of PD-L1 by tumor cells is a relatively common
event in melanoma disease (35% of patients being PD-L1+ in
the current series). Furthermore, the ﬁnding that 71% of the
PD-L1+ cases were identiﬁed in patients with stage M1C
compared with 18% of positivity in stage M1a patients supports
our previous clinical and in vitro data suggesting that PD-L1 ex-
pression marks a subset of melanomas characterized by a more
aggressive disease [8].
The molecular mechanisms behind the constitutive oncogenic
driven upregulation of PD-L1 have not been clariﬁed yet. In a
study using glioblastoma cell lines, Parsa et al. found that the
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Figure 3. Kaplan–Meier curves showing progression-free survival, PFS (A) and overall survival, OS (B) of metastatic melanoma patients (MMP) according to
the combination of PD-L1 membrane expression and density of tumor-inﬁltrating mononuclear immune cells (TIMC) in metastatic tumor samples.
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mutation and loss of PTEN was associated with increased PD-
L1 expression [16]. However, our preclinical data (supplemen-
tary Table S3, available at Annals of Oncology online) and those
reported in a recent study did not replicate the same ﬁndings in
melanoma models [17], suggesting that different molecular cir-
cuits may be active in melanoma. However, it should be noticed
that we did not check for PTEN deletion in our clinical series,
leaving room for future studies.
A major challenge in the PD-L1 ﬁeld concerns the availability
of easy-to-use and reliable antibodies for tissue staining. In our
study, comparative analysis indicated that both monoclonal
antibodies, 5H1 and rabbit clone E1L3N mAb, yield reliable
results. When we compared the staining pattern of 5H1 and
E1L3N mAb, we found no discrepancies in number of positive
cases, but the fully automatic staining procedure of E1L3N mAb
represents a clear advantage in routine practice.
Two recent studies found a frequently discordant PD-L1 expres-
sion between primary and metastatic samples and between intra-
patient metastases [8, 18]. Considering that PD-L1 expression in
primary melanoma is unreliable as predictor of PD-L1 expression
in distant metastases, we herein selected for analysis the most
recent metastatic melanoma tissue specimen, and preferentially
large excision biopsies, rather than small core or ﬁne-needle
biopsy samples. Nevertheless, the clinical impact of the heteroge-
neous PD-L1 expression in multiple distant metastases from the
same patient remains to be elucidated. When patients evaluated at
primary melanoma were excluded from the analysis the prognostic
role of PD-L1 remained statistically signiﬁcant (P < 0.0001).
This study has several strengths, including: (i) the novelty of
our ﬁndings, since this is the ﬁrst time that a negative immuno-
logic biomarker has been found, and this study adds further
evidence to the strict relationship between BRAFi, the immune
markers and the microenvironment; (ii) in the present study,
patients have been enrolled over the last 4 years, and all have
been homogeneously treated with BRAFi, within a single center;
(iii) PD-L1 IHC evaluation was carried out mostly (63/80, 80%)
in metastatic samples to reduce the potential discordance
between primary and metastatic samples [18] and to better
reﬂect the actual PD-L1 biological status of the patient cohort.
We are aware of the limitations of our report, namely: (i) this
is a monoinstitutional retrospective study and a validation
dataset is needed; (ii) in our patient cohort, no patient received
BRAF and MEK inhibitors, which are now known to improve
RR, PFS and OS, when compared with BRAFi alone [19–21];
(iii) we did not evaluate the immunophenotype of immune cell
inﬁltration, and the absence of CD8 staining that has been
widely used in previous studies in association with PD-L1 ex-
pression and could give more quantitative and reliable results
regarding the immune inﬁltrate. Insights on the contribution of
the speciﬁc immune inﬁltration phenotype components that
correlate with response to BRAFi would certainly be critical in
instructing how targeted and immunological treatments may be
used in combination for clinical trials.
It is intriguing that, in our study, the degree of TIMC inﬁltra-
tion assessed by simple evaluation of H&E staining tumor sec-
tions has prognostic and predictive value, despite a lack of
detailed information on the immune phenotype of the inﬁltrate.
The inclusion of TIMC assessment in metastatic samples seems
to mirror the efﬁcacy of each individual patient’s antitumor
immune response. Extension of this observation to clinical prac-
tice would require a standardized scoring methodology.
From a schematic point of view, the PD-1/PD-L1 cross-talk
could take place in the context of tumor/T-cell or APC/T-cell
interactions. In general, the tumor–T-cell context is the most
studied. In melanoma models, PD-L1 expression by tumor cells
may be geographically associated with inﬁltrating immune cells
and with expression of PD-1 on neighboring lymphocytes. The
subgroup of patients with PD-L1 expression, particularly on the
CD8 subset, and inﬁltrating lymphocytes shows better prognosis
than the group with PD-L1 expression without inﬁltrating lym-
phocytes [10]. However, PD-L1 positivity can be found also in
melanoma samples without tumor lymphocyte inﬁltration and, in
this subgroup of patients, it is unclear whether the lack of T-cell in-
ﬁltration reﬂects the absence of tumor antigen-speciﬁc responses
or an unidentiﬁed process that excludes lymphocytes inﬁltration
from the microenvironment. Hence, PD-L1 expression should be
interpreted in the context of the microenvironment as well as the
immune cells phenotype.
Since PD-L1 overexpressing melanoma patients are at higher
risk of developing early progression and worse outcome than
those who are PD-L1 negative, a different strategy should prob-
ably be pursued in these patients. Whether starting with anti
PD-1 antibodies may result in a better outcome should be evalu-
ated in ad hoc designed studies, since PD-L1 positive melano-
mas with immune cell inﬁltration seem to beneﬁt particularly
from anti PD-1 antibodies [22, 23].
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Pazopanib in pretreated advanced neuroendocrine
tumors: a phase II, open-label trial of the Spanish Task
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Background: The management of advanced neuroendocrine tumors (NETs) has recently changed. We assessed the
activity of pazopanib after failure of other systemic treatments in advanced NETs.
Methods: This was a multicenter, open-label, phase II study evaluating pazopanib as a single agent in advanced NETs
(PAZONET study). The clinical beneﬁt rate (CBR) at 6 months was the primary end point. Translational correlation of
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